For the quarter ending 2026-03-31, CBIO made $1,039K in revenue. -$23,283K in net income. Net profit margin of -2240.90%.
| Income Statement | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
|---|---|---|---|---|
| License agreement revenue | 1,039 | 2,711* | - | - |
| Research and development | 17,903 | 77,694* | 20,347 | - |
| General and administrative | 7,865 | 8,776* | 5,538 | - |
| Total operating expenses | 25,768 | 86,470* | 25,885 | - |
| Loss from operations | -24,729 | -83,759* | -25,885 | -21,030 |
| Interest income | 1,446 | 489* | 1,278 | 313 |
| Interest expense | 0 | 576* | 0 | 1,073 |
| Loss before provision for income taxes | - | -83,846* | - | - |
| Provision for income taxes | - | 500* | - | - |
| Total other income (expense) | 1,446 | - | 1,278 | -760 |
| Net loss and comprehensive loss | -23,283 | -84,346 | -24,607 | -21,790 |
| Net loss and comprehensive loss | -23,283 | -84,346 | -24,607 | -21,790 |
CRESCENT BIOPHARMA, INC. (CBIO)
CRESCENT BIOPHARMA, INC. (CBIO)